Referenties

1.
Impressie benchmark medische technologie. (2014).
2.
Prismant. Rekenschema voor zorginstellingen. (2015).
3.
Kostprijsonderzoek Medisch Specialistische Zorg (MSZ). (2016).
4.
Kostenonderzoek langdurige zorg. (2018).
5.
Monitor Toegankelijkheid van Zorg - Gevolgen van COVID-19. (2019).
6.
Kosten van ziekten. (2019).
7.
Rekentool kostprijs WMO. (2020).
8.
Sektorkompas Ambulancezorg: Tabellenboek 2019. (2020).
9.
CBS StatLine - Arbeidskosten; structuur arbeidskosten, -duur, bedrijfstak SBI2008. (2020).
10.
Brancherapport Revalidatie 2020. (2020).
11.
Adviesbrief aan VWS Beschikbaarheidbijdrage SEH- Rapport Kostenonderzoek beschikbaarheidbijdrage spoedeisende hulp t.b.v. Marktverstoringstoets 2021. (2021).
12.
ACM Vervoersmonitor 2019. (2021).
13.
Kamerstuk: Initiatiefnota 35766. (2021).
14.
Factsheet Geriatrische Revalidatiezorg. (2021).
15.
CBS StatLine - Zorginstellingen; kerncijfers. (2021).
16.
CBS StatLine - Zorginstellingen; financiën en personeel. (2021).
17.
Cao universitair medische centra 2022-2023. (2022).
18.
CAO Huisartsenzorg. (2022).
19.
Autokosten. (2022).
20.
Tariefbeschikking Regionale Ambulancevoorzieningen TB/REG-22629-01. (2022).
21.
Practical application to include disease costs (PAID). (2022).
22.
Collectieve Arbeidsovereenkomst Ziekenhuizen 2021-2023. (2022).
23.
CBS StatLine - Zorguitgaven internationaal vergelijkbaar; functies, aanbieders, 1998-2022. (2022).
24.
CAO Verpleeg-, Verzorginshuizen, Thuiszorg en Jeugdgezondheidszorg 2022-2023. (2022).
25.
CBS StatLine - Nabijheid voorzieningen; afstand locatie, regionale cijfers. (2023).
26.
CAO Eerstelijn Fysiotherapie. (2023).
27.
Belastingplan 2023. (2023).
28.
Zorgcijfersdatabank - Totale zorgkosten Wet Langdurige Zorg. (2023).
29.
Zorgcijfersdatabank - Paramedische Zorg. (2023).
30.
Zorgcijfersdatabank - Huisartsenzorg en Multidisciplinaire zorg. (2023).
31.
Tarieven gebruik Taxi. (2023).
32.
Statline. (2023).
33.
Schooltijden en onderwijstijd. (2023).
34.
Passend onderwijs. (2023).
35.
Harmonised index of consumer prices - monthly data. (2023).
36.
GIPdatabank. (2023).
37.
CBS StatLine - Consumentenprijzen; prijsindex. (2023).
38.
Btw-tarieven. (2023).
39.
Asselman, F. F. Kostprijzen in Ziekenhuizen. (Springer, 2008).
40.
Bouwmans, C. et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Services Research 13, 217 (2013).
41.
Bouwmans, C. et al. The iMTA Productivity Cost Questionnaire. Value in Health 18, 753–758 (2015).
42.
Briggs, A. H., Claxton, K. & Sculpher, M. J. Decision Modelling for Health Economic Evaluation. (Oxford University Press, 2006).
43.
Brouwer, W. B. F., Koopmanschap, M. A. & Rutten, F. F. H. Patient and Informal Caregiver Time in Cost-Effectiveness Analysis: A Response to the Recommendations of the Washington Panel. International Journal of Technology Assessment in Health Care 14, 505–513 (1998).
44.
Brouwer, W., Verbooy, K., Hoefman, R. & van Exel, J. Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects. PharmacoEconomics (2023) doi:10.1007/s40273-023-01253-y.
45.
Clement (Nee Shrive), F. M., Ghali, W. A., Donaldson, C. & Manns, B. J. The impact of using different costing methods on the results of an economic evaluation of cardiac care: Microcosting vs gross-costing approaches. Health Economics 18, 377–388 (2009).
46.
Davidoff, A. J. & Powe, N. R. The role of perspective in defining economic measures for the evaluation of medical technology. International Journal of Technology Assessment in Health Care 12, 9–21 (1996).
47.
DeSocio, J. & Hootman, J. Children’s Mental Health and School Success. The Journal of School Nursing 20, 189–196 (2004).
48.
Drost, R. M. W. A. Handleiding intersectorale kosten en baten van (preventieve) interventies: classificatie, identificatie en kostprijzen. (Datawyse, 2014).
49.
Drost, R. M. W. A., Paulus, A. T. G., Ruwaard, D. & Evers, S. M. A. A. Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: Methods for obtaining unit prices. Expert Review of Pharmacoeconomics & Outcomes Research 17, 77–84 (2017).
50.
Drummond, M., Sculpher, M., Claxton, K., Stoddart, G. & Torrance, G. Methods for Economic Evaluation of Health Care Programmes. (Oxford University Press, 2015).
51.
Eeren, H. V., Schawo, S. J., Scholte, R. H. J., Busschbach, J. J. V. & Hakkaart, L. Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration. PLOS ONE 10, e0131255 (2015).
52.
Eggink, E. et al. Publiek voorzien: Ontwikkelingen in de uitgaven en dienstverlening van 27 publieke voorzieningen. (Sociaal en Cultureel Planbureau, 2018).
53.
Ellwein, L. B. & Drummond, M. F. Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes. International Journal of Technology Assessment in Health Care 12, 691–697 (1996).
54.
Farrington, D. P. Age and Crime. Crime and Justice 7, 189–250 (1986).
55.
Franken, M. G. et al. Potential cost savings owing to the route of administration of oncology drugs: A microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs 29, 791–801 (2018).
56.
Gandjour, A. & Lauterbach, K. W. Does prevention save costs? Journal of Health Economics 24, 715–724 (2005).
57.
Gheorghe, M., Hoefman, R. J., Versteegh, M. M. & van Exel, J. Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. PharmacoEconomics 37, 93–103 (2019).
58.
Gold, M. R. Cost-effectiveness in health and medicine. (Oxford University Press, 1996).
59.
Goorden, M. et al. The cost-effectiveness of family/family-based therapy for treatment of externalizing disorders, substance use disorders and delinquency: A systematic review. BMC psychiatry 16, 237 (2016).
60.
Goorden, M., van der Schee, E., Hendriks, V. M. & Hakkaart-van Roijen, L. Cost-effectiveness of multidimensional family therapy compared to cognitive behavioral therapy for adolescents with a cannabis use disorder: Data from a randomized controlled trial. Drug and Alcohol Dependence 162, 154–161 (2016).
61.
Hoefman, R. J., van Exel, J. & Brouwer, W. How to Include Informal Care in Economic Evaluations. PharmacoEconomics 31, 1105–1119 (2013).
62.
Janssen, L. M. M. et al. Exploring the identification, validation, and categorization of the cost and benefits of criminal justice in mental health: The PECUNIA project. International Journal of Technology Assessment in Health Care 36, 418–425 (2020).
63.
Johnston, K., Buxton, M. J., Jones, D. R. & Fitzpatrick, R. Assessing the costs of healthcare technologies in clinical trials. Health Technology Assessment (Winchester, England) 3, 1–76 (1999).
64.
Kellerborg, K., Perry-Duxbury, M., de Vries, L. & van Baal, P. Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0. Value in Health 23, 1453–1461 (2020).
65.
Kellerborg, K., Wouterse, B., Brouwer, W. & van Baal, P. Estimating the costs of non-medical consumption in life-years gained for economic evaluations. Social Science & Medicine 289, 114414 (2021).
66.
Koopmanschap, M. A. & Rutten, F. F. H. A Practical Guide for Calculating Indirect Costs of Disease: PharmacoEconomics 10, 460–466 (1996).
67.
Krol, M., Brouwer, W. & Rutten, F. Productivity Costs in Economic Evaluations: Past, Present, Future. PharmacoEconomics 31, 537–549 (2013).
68.
Krol, M. & Brouwer, W. How to Estimate Productivity Costs in Economic Evaluations. PharmacoEconomics 32, 335–344 (2014).
69.
Krol, M. & Brouwer, W. Unpaid work in health economic evaluations. Social Science & Medicine 144, 127–137 (2015).
70.
Leggett, L. E. et al. Measuring Resource Utilization: A Systematic Review of Validated Self-Reported Questionnaires. Medicine 95, e2759 (2016).
71.
Mason, J. The Generalisability of Pharmacoeconomic Studies. PharmacoEconomics 11, 503–514 (1997).
72.
McCollister, K. E., French, M. T., Sheidow, A. J., Henggeler, S. W. & Halliday-Boykins, C. A. Estimating the differential costs of criminal activity for juvenile drug court participants: Challenges and recommendations. The Journal of Behavioral Health Services & Research 36, 111–126 (2009).
73.
Meijer, R. F. et al. Criminaliteit en rechtshandhaving 2021. (2022).
74.
(NZa), N. Z. Beleidsregel bijzondere tandheelkunde instellingen. (2022).
75.
Patel, S. et al. Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room. International Journal of Health Policy and Management 1 (2020) doi:10.34172/ijhpm.2020.119.
76.
Payne, G., Laporte, A., Deber, R. & Coyte, P. C. Counting Backward to Health Care’s Future: Using Time-to-Death Modeling to Identify Changes in End-of-Life Morbidity and the Impact of Aging on Health Care Expenditures. The Milbank Quarterly 85, 213–257 (2007).
77.
Polder, J. J., Barendregt, J. J. & van Oers, H. Health care costs in the last year of life experience. Social Science & Medicine 63, 1720–1731 (2006).
78.
Polsky, D. & Glick, H. Costing and Cost Analysis in Randomized Controlled Trials: Caveat Emptor. PharmacoEconomics 27, 179–188 (2009).
79.
Potter, S., Davies, C., Davies, G., Rice, C. & Hollingworth, W. The use of micro-costing in economic analyses of surgical interventions: A systematic review. Health Economics Review 10, 3 (2020).
80.
Raikou, M., Briggs, A., Gray, A. & McGuire, A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Economics 9, 191–198 (2000).
81.
Ramsey, S. D. et al. Cost-Effectiveness Analysis Alongside Clinical Trials II. Value in Health 18, 161–172 (2015).
82.
Reckers-Droog, V. T. et al. Unit Costs of Delinquent Acts for Use in Economic Evaluations. The Journal of Mental Health Policy and Economics 22, 71–79 (2019).
83.
Rutten-van Mölken, M. P. M. H. Van kosten tot effecten: Een handleiding voor evaluatiestudies in de gezondheidszorg. (Elsevier Gezondheidszorg, 2010).
84.
Schawo, S. J. et al. Framework for modelling the cost-effectiveness of systemic interventions aimed to reduce youth delinquency. The Journal of Mental Health Policy and Economics 15, 187–196 (2012).
85.
St-Hilaire, C. & Crépeau, P. K. Méthode de répartition des coûts unitaires et des coûts hospitaliers. Healthcare Management Forum 13, 12–24 (2000).
86.
Swanborn, P. G. Methoden van sociaal-wetenschappelijk onderzoek. (Boom Onderwijs, 2010).
87.
Tan, S. S. Microcosting in economic evaluations: Issues of accuracy, feasibility, consistency and generalisability. (2009).
88.
Tan, S. S., Rutten, F. F. H., van Ineveld, B. M., Redekop, W. K. & Hakkaart-van Roijen, L. Comparing methodologies for the cost estimation of hospital services. The European Journal of Health Economics 10, 39–45 (2009).
89.
Tan, S. S. et al. DRGs and cost accounting: Which is driving which. in Diagnosis-related groups in Europe: Moving towards transparency, efficiency and quality in hospitals. Buckingham, Open University Press and WHO Regional Office for Europ 59–74 (2011).
90.
Tan, S. S., van Ineveld, B. M., Redekop, W. K. & Hakkaart-van Roijen, L. Cost assessment and price setting of hospital care in the Netherlands: The DBC casemix system. in Diagnosis-related groups in Europe: Towards efficiency and quality (Open University Press, 2011).
91.
van Baal, P. H. M. et al. Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations: PharmacoEconomics 29, 175–187 (2011).
92.
van Baal, P. H. M., Feenstra, T. L., Polder, J. J., Hoogenveen, R. T. & Brouwer, W. B. F. Economic evaluation and the postponement of health care costs. Health Economics 20, 432–445 (2011).
93.
van den Hout, W. B. The value of productivity: Human-capital versus friction-cost method. Annals of the Rheumatic Diseases 69, i89–i91 (2010).
94.
Van der Laan, A. M., Beerthuizen, M. G. C. J. & Boot, N. C. Monitor Jeugdcriminaliteit. (2020).
95.
van der Poll, P., Lo - van Steenbergen, E., Prins, S. & Bex, P. Kostprijsonderzoek geestelijke gezondheidszorg en forensische zorg 2020. (2020).
96.
Verbooy, K., Hoefman, R., van Exel, J. & Brouwer, W. Time Is Money: Investigating the Value of Leisure Time and Unpaid Work. Value in Health 21, 1428–1436 (2018).
97.
Vermeulen, K. M., Jansen, D. E. M. C., Knorth, E. J., Buskens, E. & Reijneveld, S. A. Cost-effectiveness of multisystemic therapy versus usual treatment for young people with antisocial problems: Cost-effectiveness of multisystemic therapy. Criminal Behaviour and Mental Health 27, 89–102 (2017).
98.
Wordsworth, S., Ludbrook, A., Caskey, F. & Macleod, A. Collecting unit cost data in multicentre studies: Creating comparable methods. The European Journal of Health Economics 6, 38–44 (2005).
99.
Zorgcijfersdatabank - Verblijf Verpleging en Verzorging.
100.
Zuurbier, J. & Krabbe-Alkemade, Y. Onderhandelen over DBC’s. (Elsevier gezondheidszorg, 2007).